PTC Therapeutics
PTCT
353 hedge funds and large institutions have $7.04B invested in PTC Therapeutics in 2025 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 126 increasing their positions, 96 reducing their positions, and 37 closing their positions.
173% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 37
39% more capital invested
Capital invested by funds: $5.07B → $7.04B (+$1.97B)
31% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 96
28% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $17.4M
20% more funds holding
Funds holding: 294 → 353 (+59)
11.39% more ownership
Funds ownership: 104.08% → 115.48% (+11%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$410M |
| 2 |
Janus Henderson Group
London,
|
+$78.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$77.9M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$64.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$58.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$76.4M |
| 2 |
Millennium Management
New York
|
-$75.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$41.9M |
| 4 |
AC
Armistice Capital
New York
|
-$34.5M |
| 5 |
D.E. Shaw & Co
New York
|
-$31.2M |
PTCT Hedge Fund Activity: Q4 2025 in Review
353 of the 8,263 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2025, worth a combined $7.04B — up 39% from $5.07B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new PTCT positions and 37 closed out — a net gain of 64 holders — while 126 added to existing stakes and 96 trimmed.
The largest buyer was BlackRock, adding an estimated $410M. The largest seller was Wellington Management Group, cutting an estimated $76.4M.
- 353 institutional investors held PTC Therapeutics (PTCT) as of Q4 2025, up from 294 in Q3 2025.
- Funds reported $7.04B of PTC Therapeutics stock for Q4 2025, up 39% quarter-over-quarter.
- 101 funds opened new PTC Therapeutics positions in Q4 2025 and 37 closed out, a net change of +64 holders.
- The largest PTC Therapeutics buyer in Q4 2025 was BlackRock, an estimated $410M added.
- The largest PTC Therapeutics seller in Q4 2025 was Wellington Management Group, an estimated $76.4M sold.
Based on aggregated 13F filings for Q4 2025.